Ask AI
Back Back
Frontline CLL Treatment
International Perspectives on Developments and Decision-making Tools for Frontline Treatment of CLL/SLL

Released: February 17, 2026

Stephan Stilgenbauer
Stephan Stilgenbauer, MD
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Fixed duration regimens such as acalabrutinib + venetoclax ± obinutuzumab (now approved by the European Medicines Agency) and venetoclax + ibrutinib or obinutuzumab (shown to be non-inferior to continuous ibrutinib in the CLL17 trial) have an increasing role in frontline treatment of CLL.
  • For expert guidance in frontline CLL treatment choice from 5 experts in different patient scenarios, visit our interactive treatment decision support tool.

Over the last decade, the development of targeted treatments, including BTK inhibitors and BCL2 inhibitors, has greatly expanded the number of treatment options we have for previously untreated chronic lymphocytic leukemia (CLL). In the last year, we have seen several exciting developments that are further complicating the frontline treatment paradigm. To assist health care professionals (HCPs) in choosing treatment for newly diagnosed CLL, I worked with 4 other experts from various countries to develop an interactive treatment decision support tool offering tailored frontline treatment recommendations based on specific patient case details. These recommendations consider CLL genetics, patient age and fitness, and a variety of specific comorbidities. In this commentary, I will discuss the recent developments regarding frontline treatment of CLL and how to use the treatment decision support tool.

European Medicines Agency (EMA) Approval of Acalabrutinib With Venetoclax With or Without Obinutuzumab

The latest update in frontline treatment of CLL has been the approval of fixed-duration acalabrutinib with venetoclax with or without obinutuzumab for the treatment of adults with previously untreated CLL in the European Union. The doublet combination is currently under FDA review for the treatment of patients with previously untreated CLL, but acalabrutinib with venetoclax, with or without obinutuzumab, is listed in the NCCN guidelines as a preferred frontline treatment option for CLL without del(17p) or TP53 mutation. These developments were based on the interim results of the randomized phase III AMPLIFY study, first presented at the 2024 American Society of Hematology (ASH) annual meeting, comparing the 2 combination treatments vs fludarabine plus cyclophosphamide and rituximab (FCR) or bendamustine plus rituximab (BR) in patients with previously untreated CLL and no del(17p) or TP53 mutation. The interim analysis reported a superior median progression-free survival (PFS) for both acalabrutinib plus venetoclax vs FCR or BR (HR: 0.65; P = .0038) and acalabrutinib plus venetoclax with obinutuzumab (HR: 0.42; P <.0001). PFS benefits were also observed in the subgroup of patients with unmutated IGHV (HR: 0.69 and 0.35).

Acalabrutinib with venetoclax, with or without obinutuzumab, provides another valuable treatment option of finite duration for our patients. The triplet combination leads to improved efficacy but also increased toxicity compared to the doublet and may be a better option for fit patients. The place of acalabrutinib/venetoclax and acalabrutinib/venetoclax/obinutuzumab as compared to ibrutinib/venetoclax, obinutuzumab/venetoclax, and continuous BTK inhibitor therapy may be settled with longer follow-up of AMPLIFY.

Newly Reported Clinical Trials at ASH 2025

More recently, we have seen the first results of several clinical trials in the frontline setting for CLL reported at ASH 2025. For instance, the phase III CLL17 trial is the first randomized clinical trial directly comparing fixed-duration vs continuous treatment approaches, evaluating continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for previously untreated CLL. The study reported a noninferior PFS for the 2 fixed-duration treatments compared to continuous ibrutinib (3-year PFS rates of 79-81%). Overall survival was also similar between the arms (3-year overall survival rates of 92-96%). These data support the use of ibrutinib plus venetoclax along with venetoclax plus obinutuzumab as a highly efficacious fixed-duration treatment options.

We also saw the first data reported for the noncovalent BTK inhibitor pirtobrutinib in the frontline setting for CLL. The randomized phase III BRUIN CLL-313 study reported significantly improved PFS for continuous pirtobrutinib compared to fixed-duration BR (HR: 0.199; P <.0001). Meanwhile, the randomized phase III BRUIN CLL-314 trial compared pirtobrutinib to ibrutinib for both previously untreated and relapsed/refractory CLL. An exploratory analysis of the treatment-naive population demonstrated improved objective response rate (93% vs 86%; P = .0886) and significantly improved PFS (HR: 0.239; P = .0007) for pirtobrutinib vs ibrutinib. These efficacy results and the improved safety profile of pirtobrutinib compared to covalent BTK inhibitors suggest we may see future approval of pirtobrutinib in the frontline setting of CLL.

Choosing First-line Treatment for CLL
HCPs currently face a challenge in selecting from continuous and fixed-duration treatment options for individual treatment-naive patients. In general, we make these decisions based on several factors including del(17p) and TP53 mutation status, IGHV mutation status, as well as patient age or fitness and specific comorbidities. For instance, we may prefer to avoid a BTK inhibitor in patients with cardiac comorbidities. For patients with renal dysfunction combined with high tumor burden, we may prefer to avoid venetoclax due to the risk of tumor lysis syndrome.

Regarding logistical considerations, continuous BTK inhibitor therapy is generally more convenient to administer than venetoclax-based treatments as there is no need to monitor for tumor lysis syndrome or infusion-related reactions, as seen with obinutuzumab combinations. However, venetoclax regimens have a much lower risk for bleeding episodes and less accumulation of adverse events over time because of the fixed-duration treatment. In addition, drug approvals, availability, reimbursement, and cost impact treatment selection. Ibrutinib plus venetoclax and acalabrutinib plus venetoclax are not approved by the FDA for use in the United States, but they can be used off-label. Other countries have approved only some of these BTK inhibitors for treating CLL. Also, the cost of continuous BTK inhibitor therapy is often much higher than the cost of fixed-duration venetoclax-based treatments. A key component today is shared decision-making and recognizing the importance of patient choice after careful considerations and discussion of pros and cons of the various options.

To illustrate our expert recommendations on optimal frontline treatment, I will discuss 2 patient case examples that can be entered into the interactive treatment decision support tool.

Patient Case 1: Del(17p) and Hypertension
Let’s consider treatment options for a 70-year-old man who presents with CLL requiring frontline treatment. Del(17p) is detected in his workup, and he has a history of arterial hypertension that is currently well controlled with medication. He is under regular cardiology care and free from complaints upon exercise. For this patient, I would begin treatment with acalabrutinib or zanubrutinib, because these options provide the best efficacy and good tolerability in this population.

If we enter these patient characteristics into the treatment decision tool, we receive a range of BTK inhibitor recommendations. Most of the other experts recommended continuous BTK inhibitor monotherapy, primarily acalabrutinib and zanubrutinib—some specify 1 over another—but some also would consider ibrutinib with venetoclax as an alternative. Ibrutinib with venetoclax could be a reasonable alternative option based on the recent CLL17 study results showing good efficacy with this fixed-duration option in CLL with del(17p).

Patient Case 2: Fit Patient With IGHVm, High Tumor Burden
For a second example, let’s consider a 63-year-old female patient who presents with CLL requiring frontline treatment. No del(17p) or TP53 mutation is detected in her workup, and she has mutated IGHV. Her maximal lymph node is 5 cm and she is otherwise generally fit with normal renal function.

For this patient, I would recommend ibrutinib with venetoclax, acalabrutinib with venetoclax, or venetoclax with obinutuzumab. We see somewhat of a consensus in expert recommendations in the tool with all of the experts recommending 1 or more of these venetoclax-based regimens. One expert also suggests a covalent BTK inhibitor with or without obinutuzumab. However, this is a case where we would generally prefer fixed-duration treatment.

I encourage you to visit this tool and enter your own real or hypothetical patient cases to see our recommendations based on different presentations.

Your Thoughts
How do you approach treatment decisions with your patients with newly diagnosed CLL? Have you treated patients with acalabrutinib plus venetoclax with or without obinutuzumab? Share your experiences by leaving a comment below and answer the polling question regarding your treatment preferences.

Continue

Poll

1.

In your current practice, what is your preferred initial therapy for your patients with CLL?

Submit